> >Register Now <<

Speaker: Scott T. Aaronson, MD

The RECOVER study is a large randomized sham controlled study of vagus nerve stimulation in markedly treatment resistant depression involving 1000 participants. The first papers for the unipolar cohort have been published and submitted to the Centers for Medicare and Medicaid for re-consideration for coverage. This presentation will review the extensive database, the important lessons learned about studying severely treatment resistant depression and anticipate possible future availability of this novel therapy.

Key learning objectives include:

• Identify how to improve assessment of patient outcomes in severely treatment resistant depression.
• Recognize patient presentations with increased likelihood of benefit from vagus nerve stimulation.
• Describe the proposed mechanism of action for vagus nerve stimulation in treating depression.

Take advantage of our live Q&A session at the conclusion of the webinar.

One CME credit is available.  CE Language

*Registered attendees will receive access to the on-demand video recording by Friday, October 10, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.

When:

USA - October 7, 2025 at 8:00pm ET | 5:00pm PT
UK- October 8, 2025 at 1:00am BST
Australia- October 8, 2025 at 10:00am AEDT

Cost:

Member: $25
Trainee Member: FREE
Non-Member: $50

> >Register Now <<

About the Speaker

Scott T. Aaronson, MD
Dr. Scott Aaronson is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine, distinguished life fellow of the American Psychiatric Association, and is a fellow of the American College of Psychiatrists, the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr. Aaronson also serves on the board of the American Society for Clinical Psychopharmacology. He graduated with honors from Harvard Medical School and completed his psychiatric residency at McLean Hospital.
Dr. Aaronson is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt. He has been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS), Vagus Nerve Stimulation (VNS) and psychedelics in the treatment of severe refractory mood disorders. His paper on a five year observational study of VNS in treatment resistant depression published in 2017 in the American Journal of Psychiatry led to the Centers for Medicare and Medicaid supporting a randomized clinical trial of VNS in unipolar and bipolar depression through their Coverage with Evidence Development Program. He is on the committee that developed this study and is now in the process of publishing the results from the unipolar arm in a series of articles.